CLL: Treatment and Management Strategies for Best Outcomes - Episode 11
Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.
Related Content:
Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
The Invisibility of Blood Cancers to Others